Ovarian cancer: Linking genomics to new target discovery and molecular markers - The way ahead

Advances in Experimental Medicine and Biology

Volumn 617, Issue , 2008, Pages 23-40

  Hennessy, Bryan T ^a   Murph, Mandi ^a   Nanjundan, Meera ^a   Carey, Mark ^a   Auersperg, Nelly ^a   Almeida, Jonas ^a   Coombes, Kevin R ^a   Liu, Jinsong ^a   Lu, Yiling ^a   Gray, Joe W ^a   Mills, Gordon B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOTRANSFERASE; PLATINUM DERIVATIVE; PROTEIN P53; PROTEIN PIK3CA; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GENETICS; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; GENE EXPRESSION PROFILING; GENE INTERACTION; GENE MUTATION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HUMAN; MOLECULAR GENETICS; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; FEMALE; GENETICS; GENOME; GENOMICS; OVARY TUMOR; REVIEW;

ANIMALS; FEMALE; GENOME, HUMAN; GENOMICS; HUMANS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 46749143830     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-69080-3_3     Document Type: Conference Paper

References (50)

1. Jemal A, et al. (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5-26.
2. Cannistra SA (2004) Cancer of the ovary. N Engl J Med 351:2519-2529.
3. Hennessy BT, Mills GB, et al. (2006) Ovarian cancer: Homeobox genes, autocrine/paracrine growth, and kinase signaling. Int J Biochem Cell Biol 38:1450-1456.
4. Taylor HS, Vanden Heuvel GB, Igarashi P (1997) A conserved Hox axis in the mouse and human female reproductive system: late establishment and persistent adult expression of the Hoxa cluster genes. Biol Reprod 57:1338-1345.
5. International Collaborative Ovarian Neoplasm Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360:505-515.
6. Suzuki S, Moore III DH, Ginzinger DG, et al. (2000) An approach to analysis of large-scale correlations between genome changes and clinical endpoints in ovarian cancer. Cancer Res 60:5382-5385.
7. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
8. Levine DA, Bogomolniy F, Yee CJ, et al. (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res 11:2875-2878.
9. Campbell IG, Russell SE, Choong DY, et al. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64:7678-7681.
10. Shih IeM, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511-1518.
11. Narod SA, Boyd J (2002) Current understanding of the epidemiology and clinical implications of BRCA1 and BRCA2 mutations for ovarian cancer. Curr Opin Obstet Gynecol 14:19-26.
12. Stephens P, Edkins S, Davies H, et al. (2005) A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat Genet 37:590-592.
13. Sjoblom T, Jones S, Wood LD, et al. (2006) The Consensus Coding Sequences of Human Breast and Colorectal Cancers. Science 314:268-274.
14. Orsulic S, Li Y, Soslow RA, et al. (2002). Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1:53-62.
15. Dinulescu DM, Ince TA, Quade BJ, et al. (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11:63-70.
16. Yang G, Rosen DG, Mercado-Uribe I, et al. (2007) Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis 28:174-182.
17. Alvero AB, Fishman DA, Qumsiyeh MB, et al. (2004) Telomerase prolongs the lifespan of normal human ovarian surface epithelial cells without inducing neoplastic phenotype. J Soc Gynecol Investig 11:553-561.
18. Auersperg N, Wong AS, Choi KC, et al. (2001) Ovarian surface epithelium: biology, endocrinology and pathology. Endocr Rev 22:255-288.
19. Zeimet AG, Marth C (2003) Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 4:415-422.
20. Wang TL, Maierhofer C, Speicher MR, et al. (2002) Digital karyotyping. Proc Natl Acad Sci USA 99:16156-16161.
21. Shih IeM, Sheu JJ, Santillan A, et al. (2005) Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci USA 102:14004-14009.
22. Hennessy BT, Nanjunden M, Cheng KW, Nolden L, Mills GB (2006) Ovarian cancer: identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer (News and Commentary). Eur J Hum Genet 14:381-383.
23. Watanabe T, Imoto I, Kosugi Y, et al. (2001) A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization. Gynecol Oncol 81:172-177.
24. Shayesteh L, Lu Y, Kuo WL, et al. (1999) PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 21:99-102.
25. Cheng KW, Lahad JP, Kuo WL, et al. (2004) The Rab 25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 10:1251-1256.
26. Eder A, Sui X, Rosen D, et al. (2005) Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci USA 102:12519-12524.
27. Brown LA, Irving J, Parker R, et al. (2006) Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 100:264-70.
28. Hughes-Davies L, Huntsman D, Ruas M, et al. (2003) EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115:523-535.
29. Anand N, Murthy S, Amann G, et al. (2002) Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nat Genet 31:301-305.
30. Schraml P, Schwerdtfeger G, Burkhalter F, et al. (2003) Combined array comparative genomic hybridization and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J Pathol 163:985-992.
31. Li P, Maines-Bandiera S, Kuo WL, et al. (2007) Multiple roles of the candidate oncogene znf217 in ovarian epithelial neoplastic progression. Int J Cancer 120:1863-73.
32. Kamikihara T, Arima T, Kato K, et al. (2005) Epigenetic silencing of the imprinted gene ZAC by DNA methylation is an early event in the progression of human ovarian cancer. Int J Cancer 115:690-700.
33. Strathdee G, Appleton K, Illand M, et al. (2001) Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 158:1121-1127.
34. Wei SH, Balch C, Paik HH, et al. (2006) Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 12:2788-2794.
35. Wright JD, Hagemann A, Rader JS, et al. (2006) Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis. Cancer 107:83-89.
36. Smith DI (2002) Transcriptional profiling develops molecular signatures for ovarian tumors. Cytometry 47:60-62.
37. Nanjundan M, Zhang F, Schmandt R, Smith-McCune K, Mills GB (2007) Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions. Oncogene 26:2574-84.
38. Charboneau L, Scott H, Chen T, et al. (2002) Utility of reverse phase protein arrays: applications to signalling pathways and human body arrays. Brief Funct Genomic Proteomic 1:305-315.
39. Sheehan KM, Calvert VS, Kay EW, et al. (2005) Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4:346-355.
40. Tibes R, Qiu Y, Lu Y, et al. (2006) Reverse phase protein array (RPPA): validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoetic stem cells (HSC). Mol Cancer Ther 5:2512-21.
41. Duffy MJ (2006) Serum tumor markers in breast cancer: are they of clinical value? Clin Chem 52:345-351.
42. Kozak KR, Su F, Whitelegge JP, et al. (2005) Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5:4589-4596.
43. Judson PL, Geller MA, Bliss RL, et al. (2003) Preoperative detection of peripherally circulating cancer cells and its prognostic significance in ovarian cancer. Gynecol Oncol 91:389-394.
44. Swisher EM, Wollan M, Mahtani SM, et al. (2005) Specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol 193:662-667.
45. Cristofanilli M, Budd GT, Ellis MJ, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. New Engl J Med 351:781-791.
46. Muller V, Stahmann N, Riethdorf S, et al. (2005) Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity. Clin Can Res 11:3678-3685.
47. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4:988-1004.
48. Wang X, Gorlitsky R, Almeida JS (2005) From XML to RDF: how semantic web technologies will change the design of 'omic' standards. Nat Biotechnol 23:1099-1103.
49. Almeida JS, C Chen, R Gorlitsky, et al. (2006) Data integration gets 'Sloppy'. Nat Biotechnol 24:1070-1071.
50. Cheng W, Liu J, Yoshida H, et al. (2005) Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 11:531-537.